Prognostic Stage IV Breast Cancer AJCC v8 Withdrawn Phase 2 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05177796Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerTreatment